From Medscape Oncology

American Society of Hematology (ASH) 2016 Annual Meeting

December 03 - 06, 2016; San Diego, California

December 03 - 06, 2016 San Diego, California

Stopping Drug Therapy for CML: EURO-SKI Results This is the largest cohort to date of patients with chronic myeloid leukemia followed after stopping treatment with tyrosine kinase inhibitors.
Medscape Medical News, December 5, 2016
ASH CAR T Cells Motoring to Market -- by Next Year? Pivotal registration trials for CAR T cell therapies have now been completed, and two products could be approved by the end of 2017.
Medscape Medical News, December 5, 2016
ASH Obinutuzumab Bests Rituximab in Advanced FL Obinutuzumab for induction and maintenance was better than the current standard of care for follicular lymphoma, but caution is warranted with chemotherapy used as part of induction.
Medscape Medical News, December 5, 2016

Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.

Gene Therapy Is 'Becoming a Clinical Reality' After setbacks that included leukemia in treated patients, there is now enthusiasm for a new approach to gene therapy using lentiviral vectors.
Medscape Medical News, Dec 17, 2015
Three-Drug Combo Now Standard in Newly Diagnosed Myeloma Data from the first randomized trial in newly diagnosed multiple myeloma should convince the skeptics that remain about the superiority of a triplet.
Medscape Medical News, Dec 7, 2015
CLL Patients With 'Dismal' Prognosis Respond to Venetoclax Venetoclax shows impressive responses in patients with relapsed/refractory CLL who harbor the 17p deletion and who tend to have worse prognoses.
Medscape Medical News, Dec 10, 2015

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Updates from ASH 2016 Coverage of key advances and expert reactions as they happened at the meeting.

Medscape Oncology Insights

Pre-Meeting Commetary

Previous Coverage